A COVID-19 patient at Norton Healthcare was the first in the world to participate in a randomized Phase 2 clinical study using low doses of the drug selinexor. This clinical trial studied the antiviral and anti-inflammatory properties of selinexor in patients with severe COVID-19. At Norton Healthcare, the study was led by Don A. Stevens, M.D., a hematologist/oncologist with Norton Cancer Institute.

Monday, April 20